Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival

• Published in: Oncotarget 2017-07, Vol.8 (30), p.50117-50123
• Main Authors: Wang, Peng-Fei, Song, Hong-Wang, Cai, Hong-Qing, Kong, Ling-Wei, Yao, Kun, Jiang, Tao, Li, Shou-Wei, Yan, Chang-Xiang
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Clinical Research Paper; Female; Glioblastoma - genetics; Glioblastoma - mortality; Glioblastoma - pathology; Humans; Inflammation - metabolism; Isocitrate Dehydrogenase - metabolism; Lymphocytes - pathology; Male; Middle Aged; Monocytes - pathology; Mutation; Neutrophils - pathology; Preoperative Period; Survival Analysis; Young Adult
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.15235

Recent studies suggest that inflammation response biomarkers are prognostic indicators of solid tumor outcomes. Here, we quantify the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in glioblastomas (GBMs), taking into consideration the role of the isocitrate dehydrogenase (IDH) mutation status. We examined 141 primary glioblastomas (pGBMs) and 25 secondary glioblastomas (sGBMs). NLRs, PLRs, and LMRs were calculated before surgery. IDH mutations were detected immunohistochemically after tumor resection, and patients' clinical outcomes were analyzed after classification into GBM, pGBM, and IDH-wild type glioblastoma (IDH-wt GBM) groups. To make comparisons, we set cutoffs for NLR, PLR and LMR of 4.0, 175.0, and 3.7, respectively. In a multivariate analysis, both NLR (HR=1.712, 95% CI 1.026-2.858, p=0.040) and PLR (HR=2.051, 95% CI 1.288-3.267, p=0.002) had independent prognostic value. While a low NLR was associated with a better prognosis only in the IDH-wt GBM group, PLR was predictive of patient survival in the GBM, pGBM, and IDH-wt GBM groups. By contrast, LMR exhibited no prognostic value for any of the 3 types of GBM.